Adaptimmune Therapeutics Plc – American Depositary (NASDAQ:ADAP) Shorts Decreased by 32.52% After Short Covering

March 17, 2018 - By reb123z

 Adaptimmune Therapeutics Plc   American Depositary (NASDAQ:ADAP) Shorts Decreased by 32.52% After Short Covering

The stock of Adaptimmune Therapeutics Plc – American Depositary (NASDAQ:ADAP) registered a decrease of 32.52% in short interest. ADAP’s total short interest was 1.07 million shares in March as published by FINRA. Its down 32.52% from 1.59M shares, reported previously. With 851,500 shares average volume, it will take short sellers 1 days to cover their ADAP’s short positions. The short interest to Adaptimmune Therapeutics Plc – American Depositary’s float is 2.33%.

The stock increased 1.10% or $0.12 during the last trading session, reaching $11.06. About 1.38 million shares traded or 156.94% up from the average. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has declined 43.56% since March 17, 2017 and is downtrending. It has underperformed by 60.26% the S&P500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $1.04 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Coverage

Among 7 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Adaptimmune Therapeutics PLC has $20.0 highest and $10.0 lowest target. $15’s average target is 35.62% above currents $11.06 stock price. Adaptimmune Therapeutics PLC had 8 analyst reports since February 25, 2016 according to SRatingsIntel. On Monday, October 24 the stock rating was downgraded by Bank of America to “Underperform”. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) earned “Buy” rating by Cowen & Co on Friday, March 16. The rating was maintained by SunTrust with “Buy” on Saturday, November 11. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) has “Buy” rating given on Tuesday, June 6 by Cowen & Co. As per Friday, March 16, the company rating was initiated by Leerink Swann. Citigroup initiated the shares of ADAP in report on Thursday, February 25 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.